Abstract

Introduction
The clinical benefit of anticoagulant treatment for various indications is offset by the risk of bleeding. The impact of bleeding related to vitamin K antagonist (VKA) use, in terms of patients' discomfort or temporary disability and in terms of both medical and socio-economic resources is not negligible1-4. However, the majority of studies have focused on major bleeding, used obsolete definitions of bleeding and have not distinguished between clinically relevant non-major bleeding (CRNMB) and minor events2,3. The International Society on Thrombosis and Haemostasis provided a standard definition of CRNMB in 2015 as those events that are not major but require any kind of medical intervention. [...]

Downloads

Authors

Laura Franco - Vascular Emergency Medicine-Stroke Unit, University of Perugia, Perugia

Cecilia Beccatini - Vascular Emergency Medicine-Stroke Unit, University of Perugia, Perugia

Simone Vanni - Department of Emergency Medicine, "Careggi" University Hospital, Florence

Rodolfo Sbrojavacca - Emergency Medicine, "Santa Maria della Misericordia" Hospital, Udine

Cinzia Nitti - Emergency Medicine, "Ospedali Riuniti Umberto I - Lancisi - Salesi", Ancona

Giorgia Manina - Emergency Medicine, Lodi Hospital, Lodi

Luca Masotti - Internal Medicine, "Santa Maria Nuova" Hospital, Florence

Fulvio Pomero - Internal Medicine, "Santa Croce" Hospital, Cuneo

Sergio Cattinelli - Emergency Medicine, "Cattinara" Hospital, Trieste

Roberto Cappelli - Internal Medicine, University of Siena, Siena

Roberta Re - Emergency Medicine, "Ospedale Maggiore della Carità", Novara, Italy

Giancarlo Agnelli - Vascular Emergency Medicine-Stroke Unit, University of Perugia, Perugia

  • Abstract viewed - 3 times
  • PDF downloaded - 1 times